Phase III, Open-label, Randomized, Multi-center Study of the Effects of Leukocyte Interleukin, Injection [Multikine] Plus Standard of Care (Surgery + Radiotherapy or Surgery + Concurrent Chemoradiotherapy) in Subjects with Advanced Primary Squamous Cell Carcinoma of the Oral Cavity / Soft Palate Versus Standard of Care Only
Latest Information Update: 19 Jun 2024
At a glance
- Drugs Buffy coat interleukins (Primary) ; Cisplatin; Cyclophosphamide; Indometacin; Multivitamin; Zinc
- Indications Carcinoma; Head and neck cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer; Tongue cancer
- Focus Registrational; Therapeutic Use
- Acronyms IT-MATTERS
- Sponsors CEL-SCI Corporation
- 18 Jun 2024 According to a CEL-SCI media release, data from this trial presented at the International Drug Discovery Science & Technology (IDDST) 20th Annual Congress in Budapest
- 18 Jun 2024 Results published in the CEL-SCI Media Release
- 15 Feb 2024 According to a CEL-SCI media release, company plans to submit target population data to the U.S. Food and Drug Administration (FDA) this quarter Q1 2024, also Meetings with the UK regulators and the EMA are expected in H1 2024.